Direct comparison
IND vs. IDE: FDA Pathways Compared
IND (21 CFR 312, drugs/biologics) vs. IDE (21 CFR 812, devices): different FDA centers, review clocks, and risk-tier rules explained.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · free to try
Ask about IND vs. IDE: FDA Pathways Compared
Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.
An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do IND, IDE compare side by side?
The table below compares IND, IDE across 6 procurement-relevant dimensions, from what it covers through typical downstream marketing pathway.
Side-by-side comparison
| Dimension | IND | IDE |
|---|---|---|
| What it covers | Investigational drugs and biologics | Investigational medical devices |
| Governing regulation | 21 CFR Part 312 | 21 CFR Part 812 |
| Reviewing FDA center | CDER (drugs) or CBER (biologics) | CDRH |
| Default timing model | 30-day default review; sponsor may proceed unless FDA imposes a clinical hold | Significant-risk studies generally need affirmative FDA approval before enrollment; non-significant-risk studies typically proceed on IRB approval alone |
| Risk-tier fork | None — same framework applies regardless of the drug's risk level | Central — significant risk (SR) vs. non-significant risk (NSR) determination drives which procedural track applies |
| Typical downstream marketing pathway | New Drug Application (NDA) or Biologics License Application (BLA) | 510(k), De Novo, or Premarket Approval (PMA) |
Common questions
Common questions about IND vs IDE
Can a single study need both an IND and an IDE?
+
Yes — combination products (e.g., a drug-device combination) can require submissions under both Part 312 and Part 812. FDA assigns a lead center based on the product's primary mode of action.
Is an IDE the same as a 510(k)?
+
No. An IDE authorizes investigational use of a device to generate data; a 510(k) is a subsequent marketing submission showing substantial equivalence to an already-legally-marketed device.
Do all device studies require FDA to formally approve an IDE application?
+
No. Non-significant risk (NSR) device studies typically proceed on IRB approval alone under abbreviated IDE requirements, without a separate FDA submission. Significant risk (SR) studies generally require both IRB and FDA approval.
